Autolus Therapeutics (AUTL)
Autolus Therapeutics Statistics
Share Statistics
Autolus Therapeutics has 266.12M shares outstanding. The number of shares has increased by 0.07% in one year.
| Shares Outstanding | 266.12M |
| Shares Change (YoY) | 0.07% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 67.03% |
| Shares Floating | 240.31M |
| Failed to Deliver (FTD) Shares | 13.63K |
| FTD / Avg. Volume | 0.99% |
Short Selling Information
The latest short interest is 8.38M, so 3.15% of the outstanding shares have been sold short.
| Short Interest | 8.38M |
| Short % of Shares Out | 3.15% |
| Short % of Float | 3.54% |
| Short Ratio (days to cover) | 5.64 |
Valuation Ratios
The PE ratio is -5.38 and the forward PE ratio is -2.66. Autolus Therapeutics's PEG ratio is 0.23.
| PE Ratio | -5.38 |
| Forward PE | -2.66 |
| PS Ratio | 659.71 |
| Forward PS | 0.9 |
| PB Ratio | 10.05 |
| P/FCF Ratio | -7.15 |
| PEG Ratio | 0.23 |
Enterprise Valuation
Autolus Therapeutics has an Enterprise Value (EV) of 933.59M.
| EV / Earnings | -4.48 |
| EV / Sales | 549.82 |
| EV / EBITDA | -5.96 |
| EV / EBIT | -4.79 |
| EV / FCF | -5.96 |
Financial Position
The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.48.
| Current Ratio | 6.15 |
| Quick Ratio | 6.15 |
| Debt / Equity | 0.48 |
| Total Debt / Capitalization | 32.21 |
| Cash Flow / Debt | -2.75 |
| Interest Coverage | -4.33 |
Financial Efficiency
Return on equity (ROE) is -1.87% and return on capital (ROIC) is -118.59%.
| Return on Equity (ROE) | -1.87% |
| Return on Assets (ROA) | -0.56% |
| Return on Capital (ROIC) | -118.59% |
| Revenue Per Employee | 3.67K |
| Profits Per Employee | -450.07K |
| Employee Count | 463 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -19K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -72.23% in the last 52 weeks. The beta is 2.02, so Autolus Therapeutics's price volatility has been higher than the market average.
| Beta | 2.02 |
| 52-Week Price Change | -72.23% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 29.45 |
| Average Volume (20 Days) | 1.38M |
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 1.7M and earned -208.38M in profits. Earnings per share was -1.2.
| Revenue | 1.7M |
| Gross Profit | -4.87M |
| Operating Income | -195.03M |
| Net Income | -208.38M |
| EBITDA | -156.77M |
| EBIT | -195.03M |
| Earnings Per Share (EPS) | -1.2 |
Balance Sheet
The company has 239.57M in cash and 52.97M in debt, giving a net cash position of 186.6M.
| Cash & Cash Equivalents | 239.57M |
| Total Debt | 52.97M |
| Net Cash | 186.6M |
| Retained Earnings | -878.56M |
| Total Assets | 827.49M |
| Working Capital | 665.64M |
Cash Flow
In the last 12 months, operating cash flow was -145.59M and capital expenditures -10.99M, giving a free cash flow of -156.57M.
| Operating Cash Flow | -145.59M |
| Capital Expenditures | -10.99M |
| Free Cash Flow | -156.57M |
| FCF Per Share | -0.9 |
Margins
Gross margin is -286.63%, with operating and profit margins of -11.49K% and -12.27K%.
| Gross Margin | -286.63% |
| Operating Margin | -11.49K% |
| Pretax Margin | -12.27K% |
| Profit Margin | -12.27K% |
| EBITDA Margin | -9.23K% |
| EBIT Margin | -11.49K% |
| FCF Margin | -9.22K% |
Dividends & Yields
AUTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -69.36% |
| FCF Yield | -34.01% |
Analyst Forecast
The average price target for AUTL is $10.5, which is 506.9% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.5 |
| Price Target Difference | 506.9% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -0.75 |
| Piotroski F-Score | 3 |